Cor Vasa 2014, 56(6):e463-e470 | DOI: 10.1016/j.crvasa.2014.06.004

High-dose spironolactone changes renin and aldosterone levels in acutely decompensated heart failure

João Pedro Ferreiraa,*, Mário Santosa, Sofia Almeidab, Irene Marquesa, Paulo Bettencourtc, Henrique Carvalhoa
a Centro Hospitalar do Porto, Portugal
b Climate Change Impacts, Adaptation and Mitigation Research Group (CC-IAM), Faculdade de Ciências, Universidade de Lisboa, Portugal
c Centro Hospitalar de São João, Portugal

Background: In acutely decompensated heart failure (ADHF) patients higher aldosterone levels correlate with worse post-discharge outcomes, suggesting that further modulation of the mineralocorticoid system during or immediately after hospitalization might favourably improve outcomes.

Methods and results: This was an observational, retrospective secondary analysis of a study including 100 patients with ADHF. In that study 50 patients were submitted to spironolactone treatment (50-100 mg/day). A higher proportion of patients with renin levels above 16.5 pg/mL and aldosterone levels above 100 ng/dL was observed in subjects submitted to spironolactone treatment (44.7% vs. 66.7% and 56% vs. 64.7%, respectively, both p < 0.05). In the group of patients submitted to spironolactone treatment the proportion of patients with renin and aldosterone levels above the cutoff had a significant increase from baseline to day 3 (24% to 32% and 16% to 44%, respectively, both p < 0.05). Log renin and aldosterone were higher in patients with renin and aldosterone levels above the cutoff point (both p < 0.05).

Conclusions: High-dose spironolactone added to standard ADHF therapy induces an additional increase in renin and aldosterone levels. Whether higher levels of renin and aldosterone due to the reactive response to full MRA still have prognostic value requires further investigation.

Keywords: Acute heart failure; Aldosterone; Mineralocorticoid receptor antagonism; Renin

Received: March 18, 2014; Revised: June 10, 2014; Accepted: June 13, 2014; Published: December 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H. High-dose spironolactone changes renin and aldosterone levels in acutely decompensated heart failure. Cor Vasa. 2014;56(6):e463-470. doi: 10.1016/j.crvasa.2014.06.004.
Download citation

References

  1. B. Pitt, F. Zannad, W.J. Remme, et al., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, New England Journal of Medicine 341 (10) (1999) 709-717. Go to original source... Go to PubMed...
  2. F. Zannad, J.J. McMurray, H. Krum, et al., Eplerenone in patients with systolic heart failure and mild symptoms, New England Journal of Medicine 364 (1) (2011) 11-21. Go to original source... Go to PubMed...
  3. B. Pitt, W. Remme, F. Zannad, et al., Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction, New England Journal of Medicine 348 (2003) 1309-1321. Go to original source... Go to PubMed...
  4. G. Guder, J. Bauersachs, S. Frantz, et al., Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure, Circulation 115 (13) (2007) 1754-1761. Go to original source... Go to PubMed...
  5. R. Latini, S. Masson, I. Anand, et al., The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT, European Heart Journal 25 (4) (2004) 292-299. Go to original source... Go to PubMed...
  6. K. Swedberg, P. Eneroth, J. Kjekshus, L. Wilhelmsen, Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group, Circulation 82 (5) (1990) 1730-1736. Go to original source... Go to PubMed...
  7. P. Vantrimpont, J.L. Rouleau, A. Ciampi, et al., Two-year time course and significance of neurohumoral activation in the Surv ival and Ventricular Enlargement (SAVE) Study, European Heart Journal 19 (10) (1998) 1552-1563. Go to original source... Go to PubMed...
  8. B. Michorowski, L. Ceremuzynski, The renin-angiotensin-aldosterone system and the clinical course of acute myocardial infarction, European Heart Journal 4 (4) (1983) 259-264. Go to original source... Go to PubMed...
  9. W. Wan, A.S. Powers, J. Li, et al., Effect of post-myocardial infarction exercise training on the renin-angiotensin-aldosterone system and cardiac function, American Journal of the Medical Sciences 334 (4) (2007) 265-273. Go to original source... Go to PubMed...
  10. F. Beygui, J.P. Collet, J.J. Benoliel, et al., High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction, Circulation 114 (24) (2006) 2604-2610. Go to original source... Go to PubMed...
  11. N. Girerd, P.S. Pang, K. Swedberg, et al., Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial, European Journal of Heart Failure 15 (11) (2013) 1228-1235. Go to original source... Go to PubMed...
  12. J.P. Ferreira, M. Santos, S. Almeida, et al., Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure, European Journal of Internal Medicine 25 (1) (2014) 67-72. Go to original source... Go to PubMed...
  13. R.J. Eudy, V. Sahasrabudhe, K. Sweeney, et al., The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism, Journal of Translational Medicine 9 (2011) 180. Go to original source... Go to PubMed...
  14. J. Menard, M.F. Gonzalez, T.T. Guyene, A. Bissery, Investigation of aldosterone-synthase inhibition in rats, Journal of Hypertension 24 (6) (2006) 1147-1155. Go to original source... Go to PubMed...
  15. R.M. Ortiz, M.L. Graciano, D. Seth, et al., Aldosterone receptor antagonism exacerbates intrarenal angiotensin II augmentation in ANG II-dependent hypertension. American Journal of Physiology: Renal Physiology 293 (1) (2007) F139-F147. Go to original source... Go to PubMed...
  16. H. Krum, H. Nolly, D. Workman, et al., Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients, Hypertension 40 (2) (2002) 117-123. Go to original source... Go to PubMed...
  17. M.F. Rousseau, O. Gurne, D. Duprez, et al., Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy, Journal of the American College of Cardiology 40 (9) (2002) 1596-1601. Go to original source... Go to PubMed...
  18. R.B. de Paula, A.A. da Silva, J.E. Hall, Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration, Hypertension 43 (1) (2004) 41-47. Go to original source... Go to PubMed...
  19. M.H. Weinberger, B. Roniker, S.L. Krause, R.J. Weiss, Eplerenone, a selective aldosterone blocker, in mild-to/moderate hypertension, American Journal of Hypertension 15 (8) (2002) 709-716. Go to original source... Go to PubMed...
  20. D.A. Calhoun, W.B. White, Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension, Journal of the American Society of Hypertension 2 (6) (2008) 462-468. Go to original source... Go to PubMed...
  21. G. Aguilera, Factors controlling steroid biosynthesis in the zona glomerulosa of the adrenal, Journal of Steroid Biochemistry and Molecular Biology 45 (1-3) (1993) 147-151. Go to original source... Go to PubMed...
  22. J.G. Cleland, H.J. Dargie, G.P. Hodsman, et al., Captopril in heart failure. A double blind controlled trial, British Heart Journal 52 (5) (1984) 530-535. Go to original source... Go to PubMed...
  23. G.S. Francis, J.N. Cohn, G. Johnson, et al., Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group, Circulation 87 (6 Suppl.) (1993) Vi40-Vi48.
  24. J. Romero Artaza, C.D. Carbia, M.F. Ceballo, N.B. Diaz, Red cell distribution width (RDW): its use in the characterization of microcytic and hypochromic anemias, Medicina (Buenos Aires) 59 (1) (1999) 17-22.
  25. N. Aung, H.Z. Ling, A.S. Cheng, et al., Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure, International Journal of Cardiology 168 (3) (2013) 1997-2002. Go to original source... Go to PubMed...
  26. J.P. Ferreira, M. Santos, S. Almeida, et al., Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors, Clinical Research in Cardiology 102 (10) (2013) 745-753. Go to original source... Go to PubMed...
  27. M. Olivares Jara, E. Santas Olmeda, G. Minana Escriva, et al., Red cell distribution width and mortality risk in acute heart failure patients, Medicina Clinica (Barcelona) 140 (10) (2013) 433-438. Go to original source... Go to PubMed...
  28. T. Tsutamoto, A. Wada, K. Maeda, et al., Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure, Journal of the American College of Cardiology 37 (2001) 1228-1233. Go to original source... Go to PubMed...
  29. M.A. Bailey, J.J. Mullins, C.J. Kenyon, Mineralocorticoid and glucocorticoid receptors stimulate epithelial sodium channel activity in a mouse model of Cushing syndrome, Hypertension 54 (4) (2009) 890-896. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.